Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Part of paid clinical trials in Dallas, Texas.
- Sponsor
- Auricula Biosciences Inc.
- Study ID
- NCT07148128
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
- Advanced Solid Tumors
- Advanced or Metastatic KRAS-mutant Tumor
- Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer
- Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer
- Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- WEF-001 — DRUGStarting dose of 0.3 mg/m2 q4wks IV, dose escalation
Study Details
This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.
Key Dates
- Start date
- Jul 28, 2025
- Status verified
- Jan 2026
- Primary completion
- Jan 31, 2028
- Completion
- Jan 31, 2028
Study Design
- Enrollment
- 110 participants (estimated)
- Allocation
- NA
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Dose selectionPhase 1: WEF-001 will be administered to participating patients at 1 selected dose out of 7 possible doses. Phase 2: WEF-001 will be administered to participating patients at 1 selected dose out of 2 possible doses.
Primary Outcome Measure
Phase 1: To characterize the safety and tolerability profiles of WEF-001 administered as monotherapy. [ Time Frame: Through study completion, an average of 1 year. ]
Central Contacts
- Michele Finn, MSc1-438-884-9551
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| NEXT Oncology Dallas | Dallas | Texas | 75230 | Shiraj Sen, MD, PhD (PRINCIPAL_INVESTIGATOR) |
| Next Oncology, San Antonio | San Antonio | Texas | 78229 | Anthony Tolcher, MD, FRCPC, FACP, FASCO (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Dallas, TX
Related Studies
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerPHASE2 · Recruiting · American Society of Clinical Oncology · Birmingham, Alabama
- A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced CancersPHASE1/PHASE2 · Recruiting · Regeneron Pharmaceuticals · Los Angeles, California
- A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORSPHASE1/PHASE2 · Recruiting · Jiangsu HengRui Medicine Co., Ltd. · Miami Beach, Florida
- Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASPHASE1/PHASE2 · Recruiting · Revolution Medicines, Inc. · Orange, California